Sweden's Sedana Medical Q3 sales rise as growth returns

Sedana Medical AB (publ)

22/10/2026 06:22

Overview
Sweden medtech firm's Q3 net sales rose 7% yr/yr as sales growth returned
Company posted Q3 net loss as investments in sales force increased expenses
FDA review of US drug application under way, with decision expected April 2027

Outlook
Sedana Medical expects to meet its financial guidance for the full year
Company is focused on accelerating commercial execution in core markets in the final quarter
FDA review of US New Drug Application ongoing, with PDUFA decision date set for April 16, 2027

Result Drivers
COMMERCIAL EXECUTION - Co said sharper focus on high-potential accounts and increased sales force investments contributed to sales growth in Q3
MARKET CONDITIONS - Co cited fewer ICU admissions with severe acute respiratory infections in Germany as a factor in sales decline, but noted improvement in Q3
CONTRACT MANUFACTURING MIX - Co said lower gross margin in Q3 was due to higher share of contract manufacturing sales and absence of prior one-time margin effect

Company press release: ID:nMFN6VhCjY

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
 
SEK 44.20 mln
 
Q3 Adjusted Loss Per Share
 
SEK 0.11
 
Q3 Net Loss
 
SEK 11.10 mln
 
Q3 Cash Flow From Operating Activities
 
-SEK 3 mln
 
Q3 EBITDA
 
-SEK 7 mln
 
Q3 EBIT Margin
 
-33.00%
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Reuters Recommended Reads
Oct 21 - Sweden's Getinge Q3 organic sales rise 2.1%
Oct 21 - Sweden's AddLife beats Q3 net sales expectations
Oct 21 - Medical gear maker Getinge beats Q3 profit estimates on pricing, product mix

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)